Compare AngloGold Ashanti Limited (AU) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AngloGold Ashanti Limited vs Novo Nordisk A/S — how do they compare? AngloGold Ashanti Limited trades at $98.75 (market cap $49.28B), while Novo Nordisk A/S trades at $46.04 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 4.2× AngloGold Ashanti Limited's market cap, and AngloGold Ashanti Limited pays the higher dividend (4.64%). Which is the better fit depends on your goals.
| AU | NVO | |
|---|---|---|
Market Cap | $49.28B | $207.85B |
Sector | Basic Materials | Health |
52-Week High | $128.26 | $63.98 |
52-Week Low | $52.15 | $35.29 |
Enterprise Value | $48.29B | $222.55B |
Dividend Yield | 4.64% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AngloGold Ashanti (AU) trades at $97.25, up 1.07% today, with a bullish technical signal from moving averages but overbought RSI readings. Strong fundamentals include a 26.64% net margin for 2025, robust free cash flow growth, and a $2 billion buyback program. Recent Q2 2026 earnings beat expectations, though Q4 2025 and Q2 2026 were misses. Analyst consensus is bullish with a $120.33 price target, and institutional buying has been noted in recent filings.
Outlook remains positive due to high gold prices, production growth, and shareholder returns, but risks include operational disruptions, inflation pressures, and volatile gold markets. The stock offers value with a P/E of 13.06 and strong profitability, yet investors should monitor cost inflation and geopolitical factors affecting mining operations.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AngloGold Ashanti Limited
Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.
Read more on AU →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
